Key Dates

Related Announcements

PAR-22-219 - Biology of Bladder Cancer (R21 Clinical Trial Optional)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform the applicant community of a change to the Funding Opportunity Announcement (FOA) PAR-22-219- Biology of Bladder Cancer (R21 Clinical Trial Optional).

The following section of PAR-22-219 has been amended:

Part 2. Full Text of Announcement, Section IV. Application and Submission Information, 7. Other Submission Requirements and Information

Currently reads:

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete or non-compliant will not be reviewed.

Revised to Read (in bold italics):

Important reminders:

All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.

The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

All other aspects of PAR-22-219 remain unchanged.

Inquiries

Please direct all inquiries to:

Ron Johnson, Ph.D.
National Cancer Institute (NCI))
Telephone: 240-276-6250
Email: [email protected]